Pilot Study to Assess the Validity of "Liquid Biopsy" to Improve Diagnosis, Prognostic Assessment and Disease Monitoring in Patients Undergoing Liver Transplant for Hilar and Intrahepatic Cholangiocarcinoma


About this study

The purpose of this study is to explore the application of “liquid biopsy” in the diagnosis, prognostication and monitoring of cholangiocarcinoma (CCA) patients undergoing liver transplant.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with perihilar or intrahepatic CCA undergoing liver transplant will be evaluated.
  • Single lesion ≤3 cm.
  • Absence of vascular invasion.
  • No evidence of extrahepatic disease.
  • No attempted prior resection with violation of tumor plane.
  • General eligibility as a liver transplant candidate.
  • No attempted prior resection with violation of tumor plane.

Exclusion Criteria:

  • None.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Bashar Aqel, M.D.

Open for enrollment

Contact information:

Bashar Aqel M.D.

(480) 301-6990


More information


Publications are currently not available

Mayo Clinic Footer